Published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), results of a VHIO-led study…
en_news
Led by Thierry Andre, Head of the Department of Medical Oncology at the Hôpital Saint Antoine in Paris, the phase…
Recently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the…
The journal Nature has published the results of a clinical trial led by researchers from the Clínica Universidad de Navarra…
The phase 3 EMBER-3 trial is evaluating imlunestrant, a next-generation oral selective estrogen receptor degrader (SERD), alone or in combination…
The results of the SOLTI-2103 VALENTINE clinical trial demonstrate that the antibody drug conjugate (ADC) patritumab deruxtecan at the standard…
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second-leading cause of cancer-related deaths in Europe by 2040. Unlike other…
The Vall d’Hebron Institute of Oncology (VHIO) has received one of the COFUND grants under the Marie Skłodowska-Curie Actions (MSCA)…
“Maestra con clase” is an initiative created by Mónica Tribó to design materials and products specifically for teachers. In her…
Dr. Jonathan Whitfield and Dr. Mariano Zacarías-Fluck, researchers in the Models of Cancer Therapies Group at VHIO, together with Dr….
